🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for NK/T Cell Lymphoma Nos

PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06530550Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: PI3K inhibitor Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies NCT06699771Phase 13 sites📍 Seoul📍 Seoul📍 Seoul GC Cell Corporation · Tests: GCC2005, Cyclophosphamide, Fludarabine Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma NCT07502768Phase 1, Phase 21 site📍 Shanghai Rong Tao · Tests: Tislelizumab, Zeprumetostat A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) NCT04365036Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Toripalimab, Pegaspargase, Gemcitabine, Oxaliplatin, Definitive intensity-modulated radiotherapy (IMRT) CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia NCT06696846Phase 11 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: CD70 CAR-NK Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies NCT06732492Phase 11 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: RD13-02 cell infusion Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma NCT06314334Phase 27 sites📍 Fuzhou📍 Nantong📍 Shanghai Fudan University · Tests: Sintilimab+Pegaspargase, P-GemOx, GELAD, IMRT Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma NCT04803201Phase 296 sites📍 Little Rock📍 Duarte📍 La Jolla Alliance for Clinical Trials in Oncology · Tests: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide Exercise as an Immune Adjuvant for Allogeneic Cell Therapies NCT06643221EARLY Phase 11 site📍 Tucson University of Arizona · Tests: Exercise, Isoproterenol, Placebo, Bisoprolol Fumarate Tablet 10 mg, Nadolol (1 x 80 mg) Tablets (Invamed, Inc) Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies NCT06909474Phase 11 site📍 Wuhan Chongqing Precision Biotech Co., Ltd · Tests: Anti-CD5 CAR NK cells A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy NCT07628738Phase 21 site📍 Shanghai Ruijin Hospital · Tests: reduced-intensity radiotherapy Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation NCT07256210Phase 21 site📍 Moscow Federal Research Institute of Pediatric Hematology, Oncolog… · Tests: Donor-derived Natural Killer Cell PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma NCT05662540NA1 site📍 Shanghai Ruijin Hospital · Tests: Positron Emission Tomography/Magnetic Resonance (PET/MR) PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma NCT06069830NA1 site📍 Shanghai Ruijin Hospital · Tests: 4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen sequential radiotherapy and 2 cycles of P… Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma NCT03501576n/a2 sites📍 Atlanta📍 Atlanta Emory University · Tests: Inactivated Influenza Vaccine Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma NCT05833893Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: XPO1 inhibitor A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1) NCT05984147Phase 127 sites📍 Visakhapatnam📍 Chandigarh📍 Ahmedabad Aurigene Discovery Technologies Limited · Tests: AUR108 Registry of Older Patients With Cancer NCT01137825n/a7 sites📍 Boone📍 Chapel Hill📍 Greenville UNC Lineberger Comprehensive Cancer Center Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas NCT07278856Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide A Registry for People With T-cell Lymphoma NCT05978141n/a26 sites📍 Duarte📍 San Diego📍 San Francisco Memorial Sloan Kettering Cancer Center · Tests: Optional Blood Sample and Nail Sample Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma NCT02974647Phase 210 sites📍 Miami📍 Chicago📍 Boston Memorial Sloan Kettering Cancer Center · Tests: Ruxolitinib JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06716658Phase 22 sites📍 Tianjin📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: JAK1 Inhibitor BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL NCT07678229Phase 31 site📍 Shanghai Rong Tao · Tests: GELAD regimen, MEDA regimen, LEAP regimen, High-dose methotrexate, Autologous Hematopoietic Stem Cell Transplantation PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL NCT07380984Phase 21 site📍 Shanghai Ruijin Hospital · Tests: PD-1 antibody, radiotherapy, Chidamide, golidocitinib A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma NCT07000617Phase 23 sites📍 Beijing📍 Beijing📍 Beijing Peking University Cancer Hospital & Institute · Tests: DAPT regimen plus radiotherapy Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma NCT04848064Phase 11 site📍 Columbus John Reneau · Tests: Cyclophosphamide, Fludarabine, Mogamulizumab, Natural Killer Cell Therapy, Quality-of-Life Assessment Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas NCT02859402Phase 22 sites📍 Busan📍 Daegu Keimyung University Dongsan Medical Center · Tests: Busulfan, Fludarabine A Study of Ruxolitinib and Duvelisib in People With Lymphoma NCT05010005Phase 19 sites📍 Miami📍 Boston📍 Basking Ridge Memorial Sloan Kettering Cancer Center · Tests: Ruxolitinib, Duvelisib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy